The first Moscow State Medical University named after Sechenov joined the consortium on the development of a new analgesic. The drug is designed to effectively block pain, similarly to opioid means, but without the formation of dependence.
The initial molecule of the substance was created by researchers from the Pacific Institute of Bioorganic Chemistry and the Far Eastern Federal University. The development is based on peptide, isolated from sea anemone. Specialists of Sechenov University will be engaged in improving production technology and will take part in preclined and clinical trials.
Experienced industrial production is planned to be organized at the site of the Scientific Center for virology and biotechnology “Vector”. The drug belongs to TRPV1 vanyloid modulators, which are associated with the development of pain syndromes. It also has anti -inflammatory and hypothermic effects.
At the end of the first stage of preclinical research, the effectiveness and safety of the substance was confirmed. The preparation of documentation is underway to obtain permission for clinical trials. If they pass successfully, a new remedy can be used to help oncological patients and patients after surgery.
